Ahmedabad, February 10, 2015
For the third quarter ended 31st December 2014, Cadila Healthcare Limited registered a Net Profit of Rs. 282 crores, up by 52% from Rs. 186 crores in the corresponding period last year. The company registered a Total Income from Operations of Rs. 2190 crores up by 17% from Rs. 1872 crores in the corresponding period last year, on a consolidated basis.
During the quarter, the company’s business in the US registered a growth of 42% and Emerging Markets business grew by 23%. During the quarter, the company filed 5 additional ANDAs with the US FDA taking the cumulative ANDA filings to 255.
During the quarter, the company launched Exemptia, the world’s first biosimilar for Adalimumab, the largest selling therapy worldwide for inflammatory arthritis. Exemptia is given as a 40 mg subcutaneous injection once every alternate week. The therapy is currently marketed by Zydus Biovation – a new division launched to exclusively market this ground breaking therapy.
The group’s R&D pipeline which comprises 25 biologics (incl. novel biologics), is being developed to treat auto immune disorders like arthritis, cancer, infertility and stroke.
